Anthracycline News and Research

RSS
Anthracycline is a type of antibiotic that comes from certain types of Streptomyces bacteria. Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. Daunorubicin, doxorubicin, and epirubicin are anthracyclines.
More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Genentech submits sBLAs to the FDA for Avastin

Genentech submits sBLAs to the FDA for Avastin

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

Eisai reports global Phase III study results of eribulin mesylate

Eisai reports global Phase III study results of eribulin mesylate

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

NCCN Guidelines for Acute Myeloid Leukemia updated

NCCN Guidelines for Acute Myeloid Leukemia updated

Rituxan's sBLA receives a Complete Response from the FDA

Rituxan's sBLA receives a Complete Response from the FDA

Breast cancer patients who achieve pathological complete response have better outcomes

Breast cancer patients who achieve pathological complete response have better outcomes

Orphan drug designation for pixantrone applied by Cell Therapeutics

Orphan drug designation for pixantrone applied by Cell Therapeutics

Genentech releases Phase III PRIMA study findings

Genentech releases Phase III PRIMA study findings

Phase III EXTEND trial results of pixantrone announced

Phase III EXTEND trial results of pixantrone announced

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Cytrx initiates tamibarotene and TRISENOX combination dose escalation study

Cytrx initiates tamibarotene and TRISENOX combination dose escalation study

FDA approves Supplemental New Drug Application for DOXIL

FDA approves Supplemental New Drug Application for DOXIL

FDA notifies PDUFA action date for Cell Therapeutics' NDA for pixantrone

FDA notifies PDUFA action date for Cell Therapeutics' NDA for pixantrone

Chemotherapy affects sleep-wake activity rhythms of breast cancer patients

Chemotherapy affects sleep-wake activity rhythms of breast cancer patients

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

Cell Therapeutics' NDA for Pixantrone accepted by the FDA